Publications by authors named "Ahmed Noby Amer"

2 Publications

  • Page 1 of 1

Molecular Epidemiology of HIV-1 virus in Egypt: A major change in the circulating subtypes.

Curr HIV Res 2021 Aug 4. Epub 2021 Aug 4.

Microbiology Department, Medical Research Institute, Alexandria University. Egypt.

Background: Human immunodeficiency virus type 1 (HIV-1) is characterized by high genetic diversity due to its high-mutation and recombination rates. Although, there is an increasing prevalence of circulating recombinant forms (CRFs) worldwide. Subtype B is still recognized as the predominant subtype in the Middle East and North Africa (MENA) region. There is a limited sampling of HIV in this region due to its low prevalence. The main purpose of this study is to provide a summary of the current status of the resident HIV subtypes and their distribution among Egyptian patients.

Methodology: Forty-five HIV-1 patients were included in this study. Partial pol gene covering the protease (PR) and reverse transcriptase (RT) was successfully amplified in 21 HIV patients using nested PCR of cDNA of the viral genomic RNA, then sequenced. The sequence data were used for viral HIV-1 subtyping by 5 online subtyping tools: NCBI viral genotyping tool, Stanford University HIV database (HIVDB) subtyping program, REGA tool, Context-based modeling for expeditious typing (COMET) tool, and Recombinant identification program (RIP) tool. The final subtype assignment was based on molecular phylogenetic analysis.

Results: Unexpectedly, non-B subtypes are dominating with the most common circulating one is CRF02_AG (57.1%) followed by subtype B (14.3%), subtype BG recombinant (9.5%), CRF35_AD (9.5%), subtype A1 and CRF06_cpx (4.8 % each).

Conclusion: To the best of our knowledge, this is the first study to tackle HIV-1 subtyping among the group of HIV-1 patients in Egypt. CRF02_AG is the most prevalent subtype in Egypt.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.2174/1570162X19666210805091742DOI Listing
August 2021

Transforming iodoquinol into broad spectrum anti-tumor leads: Repurposing to modulate redox homeostasis.

Bioorg Chem 2021 08 31;113:105035. Epub 2021 May 31.

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt. Electronic address:

We managed to repurpose the old drug iodoquinol to a series of novel anticancer 7-iodo-quinoline-5,8-diones. Twelve compounds were identified as inhibitors of moderate to high potency on an inhouse MCF-7 cell line, of which 2 compounds (5 and 6) were capable of reducing NAD level in MCF-7 cells in concentrations equivalent to half of their ICs, potentially due to NAD(P)H quinone oxidoreductase (NQO1) inhibition. The same 2 compounds (5 and 6) were capable of reducing p53 expression and increasing reactive oxygen species levels, which further supports the NQO-1 inhibitory activity. Furthermore, 4 compounds (compounds 5-7 and 10) were qualified by the Development Therapeutic Program (DTP) division of the National Cancer Institute (NCI) for full panel five-dose in vitro assay to determine their GI on the 60 cell lines. All five compounds showed broad spectrum sub-micromolar to single digit micromolar GI against a wide range of cell lines. Cell cycle analysis and dual staining assays with annexin V-FITC/propidium iodide on MCF-7 cells confirmed the capability of the most active compound (compound 5) to induce cell cycle arrest at Pre-G1 and G2/M phases as well as apoptosis. Both cell cycle arrest and apoptosis were affirmed at the molecular level by the ability of compound 5 to enhance the expression levels of caspase-3 and Bax together with suppressing that of CDK1 and Bcl-2. Additionally, an anti-angiogenic effect was evident with compound 5 as supported by the decreased expression of VEGF. Interesting binding modes within NQO-1 active site had been identified and confirmed by both molecular docking and dymanic experiments.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioorg.2021.105035DOI Listing
August 2021
-->